Our ambition is to change lives by changing the course of blood cancer.
We’re committed to bringing the potential power of telomerase inhibition to patients with blood cancer.
Latest Updates
Research & Development
Geron announces FDA acceptance of New Drug Application for imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS)
Learn moreResearch & Development
Events
Investor Event
Watch the replay of our fourth quarter and full year 2023 financial results webcast
Geron management shared fourth quarter and full year 2023 financial results and business highlights.
Medical Congress
Geron announces IMerge Phase 3 presentations at ASH highlighting data and analyses in lower risk MDS
Geron presented IMerge Phase 3 data at ASH that highlights significant durability of RBC transfusion independence and breadth of effect across MDS subgroups
Research & Development
What if you could kill cancer cells by targeting the enzyme that drives their uncontrolled growth?
Geron is tirelessly pursuing blood cancer treatments with the potential to extend and enhance lives through the unique mechanism of action of telomerase inhibition. Our first-in-class investigational telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease.
Learn about imetelstatPublications
Research & Development
Imetelstat in patients with lower-risk MDS who have relapsed or are refractory to erythropoiesis-stimulating agents in IMerge phase 3 trial
Platzbecker, et. al.
Research & Development
Continuous Transfusion Independence with Imetelstat in Lower Risk MDS in IMerge Phase 3
Platzbecker, et. al.
Bringing our first-in-class telomerase inhibitor, imetelstat, to patients
Learn how we’re building on Nobel Prize-winning science
We are on a mission to extend and enhance lives
Discover more about our commitment to patients